Prescription Drugs

President Barack Obama and congressional appropriators are looking for savings to offset new federal spending programs.  One proposal on the table – drawn from the president's budget plan – would disproportionately impact low-income seniors who rely on prescription medications for serious medical conditions. The measure, estimated to save $8.9 billion over ten years, would increase copayments … [Read more...] about Congress Should Say No to Cutting Drug Subsidies for Low-Income Seniors

Zeke Emanuel is tired of paying for your expensive medicine. Dr. Emanuel, who served in a senior position at the Office of Management and Budget where he contributed to the recurring nightmare known as ObamaCare, recently complained in the New York Times [“I Am Paying For Your Expensive Medicine”] that his insurance rates are high because the medicines you’re taking cost too much. “We all … [Read more...] about No, Zeke, You’re Not Paying For My Medicine

The Obama administration is proposing a Medicare payment rule that would have the effect of clamping price controls on biosimilar drugs, extending destructive pricing policies to a potentially vibrant 21st century life sciences industry. The Centers for Medicare and Medicaid Services (CMS) has proposed a rule that would guide how Medicare pays for a new class of medicines used in physicians’ … [Read more...] about CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market

Democratic presidential candidate Hillary Clinton has piled bad new ideas on top of bad old ideas with her plan to try to lower prescription drug prices in America. Her proposals to rein in prescription drug costs involve forcing pharmaceutical companies to meet a government quota for investing in research, denying companies tax breaks for consumer advertising, and capping out-of-pocket … [Read more...] about Clinton drug plan would backfire on patients

A profiteer masquerading as a pharmaceutical company executive has set the Internet afire with his 5,000% price increase for a rare but important drug used by AIDS and some cancer patients. Martin Shkreli, a 32-year-old former hedge fund manager, cornered the market on Daraprim, a drug used to treat a life-threatening parasitic infection. His start-up company, Turing Pharmaceuticals, bought … [Read more...] about A Bad-Actor, Not A Pharmaceutical Innovator, Causes Outrage Over Drug Prices

Pharmaceutical prices are dominating public concerns about health care, according to a recent poll by the Kaiser Family Foundation that shows three-quarters of Americans support limiting how much drug companies can charge for high-cost drugs.  So it’s especially disappointing to see that the first imitators of a new generation of biologic cancer drugs approved for the U.S. market will be started … [Read more...] about First Biosimilar Medicine Launches; Price Disappoints Those Hoping For Deeper Discount

The 21st Century Cures project, led by Energy and Commerce Committee Chairman Fred Upton (R-MI) and Rep. Diana DeGette (D-CO), is an extraordinarily important endeavor that recognizes the need to modernize our regulatory structure if we are to achieve the major promises of 21st century medicine. “If we want to save more lives and keep this country the leader in medical innovation, we have to … [Read more...] about ‘Forced Sale’ Of Drugs Could Endanger Patient Safety